Structure Therapeutics Inc (GPCR) - News Archive

The effective management of obesity remains a daunting challenge in pharmacotherapy, amidst rising prevalence rates and associated comorbidities. Structure Therapeutics Inc. has recently advanced its developmental pipel...

The rising prevalence of obesity has necessitated the development of effective pharmacological interventions. Structure Therapeutics oral small molecule GLP-1 receptor agonist, GSBR-1290, is currently under investigatio...

: Structure Therapeutics Inc. a clinical-stage global biopharmaceutical firm focused on developing innovative oral small molecule therapeutics for metabolic and cardiopulmonary diseases, has announced significant leader...

Structure Therapeutics Inc. recently announced the successful closing of its upsized underwritten public offering, which saw the sale of 10,427,017 American depositary shares (ADSs) at a price of $52.50 per ADS. This re...

San Francisco-based biopharmaceutical company, Structure Therapeutics Inc., recently unveiled the pricing details of its upsized underwritten public offering. The offering, comprising 9,066,972 American depositary share...

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded WarrantsSAN FRANCISCO, June 03, 2024 - Structure Therapeutics Inc. (NASDAQ: GPCR), a leading biopharmaceutical compa...

Obesity has become a global epidemic, with significant health and economic burdens. Considering the limited efficacy and potential safety concerns associated with existing anti-obesity medications, the development of no...

Structure Therapeutics, a leading biopharmaceutical company, has recently released an extensive update on their GSBR-1290 program, including encouraging proof-of-concept data from a Phase 2a clinical study. This article...